ReviewMolecular therapy. Methods & clinical development2023
Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions.
Review in Molecular therapy. Methods & clinical development, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Drivers of managed entry agreements to reduce reimbursement challenges of orphan medicinal products: the development of a matrix.Orphanet journal of rare diseases · 2025Pooled it
- Translational Progress and Clinical Challenges in Bioengineered Bone and Joint Repair.Biomedicines · 2026Review
- Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA.PharmacoEconomics · 2026Review
- Clearing the hurdles for CAR-T cell treatment.Nature reviews. Immunology · 2025Article
- [Analysis of the Incidence and Trends of Rare Diseases in the Republic of Korea in 2022].Jugan geon-gang gwa jilbyeong · 2025Article
- Toward equitable regenerative medicine: a health equity research framework for emerging regenerative treatments.Regenerative medicine · 2025Review
- How to democratize cell and gene therapy: A global approach.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges.Molecular therapy. Methods & clinical development · 2025Article
- Innovative Insurance to Improve US Patient Access to Cell and Gene Therapy.The Milbank quarterly · 2025Article
- Review
- Improving access to gene therapies: a holistic view of current challenges and future policy solutions in the United States.Journal of comparative effectiveness research · 2024Review
- A roadmap for affordable genetic medicines.Nature · 2024Review
- Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape.Healthcare (Basel, Switzerland) · 2024Article
- Bringing CAR T cell therapy trials to underserved populations.Cancer cell · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current Medicaid system is ill equipped to handle the anticipated approvals of new gene and cell therapy products. These advanced therapies tend to be single-dose, potentially durable options for a variety of indications spanning oncology, rare disease, and more. The up-front cost of these therapies contrasts with chronic care treatment, which may incur cost over the life of a patient. The cost of these innovative treatments, along with the anticipated larger patient pools, can limit patient access as Medicaid programs operate on limited or fixed budgets. Given the value of these therapies for diseases that may have large Medicaid populations, the system will need to grapple with the existing barriers to access to ensure equitable patient care. This review focuses on one such barrier, discrepancies between product indications and state Medicaid and Medicaid Managed Care Organization coverage policies, and it proposes federal policy solutions to this barrier to better accommodate the exponential growth of the gene and cell therapy pipeline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.